Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lasofoxifene for prevention of postmenopausal osteoporosis
NCT00674453Phase 2Completed
- Sponsor
- Ligand Pharmaceuticals
- Start
- Sep 2004
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in osteoporosis comparing Lasofoxifene 0.25 mg/d with Placebo (2 arms). Primary endpoint: Change in bone mineral density of the lumbar spine at 2 years. Started Sep 2004; status: completed.
02
Drugs
lasofoxifene
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00674453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00674453.